Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
収録刊行物
-
- The Lancet
-
The Lancet 402 (10408), 1133-1146, 2023-09
Elsevier BV